Feline Congestive Heart Failure

Feline congestive heart failure (CHF) is a clinical syndrome in which the heart is unable to maintain adequate cardiac output to meet the body's metabolic demands, resulting in pathological fluid accumulation in body cavities or the pulmonary interstitium [1]. It is not a primary disease in itself but rather the end-stage consequence of underlying structural cardiac disease, most commonly one of the feline cardiomyopathies [5]. Cardiomyopathies represent the most prevalent form of heart disease in adult domestic cats, with hypertrophic cardiomyopathy (HCM) accounting for the majority of CHF cases, though restrictive cardiomyopathy (RCM), dilated cardiomyopathy (DCM), and other phenotypes are also recognized causes [2][6]. CHF carries a guarded to poor prognosis and is associated with significant morbidity and mortality, making early recognition and intervention critical [1].

Primary Underlying Diseases

The vast majority of feline CHF cases arise from primary myocardial disease (cardiomyopathy). HCM—characterized by inappropriate concentric left ventricular hypertrophy in the absence of another identifiable cause—is the most common, estimated to affect approximately 15% of the domestic cat population, though most cases remain subclinical [2]. Other cardiomyopathies contributing to CHF include restrictive cardiomyopathy (RCM, characterized by severe myocardial fibrosis and impaired ventricular filling), dilated cardiomyopathy (DCM, characterized by ventricular dilation and systolic dysfunction, historically linked to taurine deficiency), arrhythmogenic right ventricular cardiomyopathy (ARVC), left ventricular non-compaction (LVNC), and non-specific/unclassified cardiomyopathy (NCM) [1][6]. Secondary causes of cardiac dysfunction such as systemic hypertension, hyperthyroidism, and acromegaly can produce phenotypic changes indistinguishable from primary HCM [1].

Pathophysiological Mechanism

In diastolic dysfunction (the dominant mechanism in HCM and RCM), the hypertrophied or fibrotic myocardium becomes stiff and non-compliant, impairing ventricular relaxation and filling [2]. This elevates left ventricular end-diastolic pressure (LVEDP), which is transmitted retrograde to the left atrium and pulmonary veins. When pulmonary capillary hydrostatic pressure exceeds oncotic pressure, fluid extravasates into the pulmonary interstitium and alveoli, producing cardiogenic pulmonary edema [4]. In systolic dysfunction (DCM), reduced myocardial contractility directly impairs forward stroke volume, triggering compensatory neurohormonal activation [6].

Neurohormonal Compensation and Its Consequences

Reduced cardiac output activates the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system as compensatory responses [3]. Angiotensin II causes vasoconstriction and promotes aldosterone release, leading to sodium and water retention by the kidneys, increased preload, and ultimately worsening congestion [3]. Chronic RAAS activation also drives a pro-fibrotic and pro-inflammatory milieu that perpetuates myocardial remodeling and further deterioration of cardiac function [3]. Left atrial enlargement—a direct consequence of chronically elevated filling pressures—predisposes to thrombus formation in the left auricle, which is the primary source of emboli causing ATE [2].

Cardiorenal Interactions

As cardiac output falls, renal perfusion pressure decreases, activating the RAAS and further compromising renal function—a bidirectional relationship termed cardiorenal syndrome (CRS) [7]. Elevated venous pressures can impair renal venous drainage, worsening renal function independent of arterial perfusion deficits [7]. Diuretic therapy, while essential for CHF management, can itself worsen azotemia, making the balance between adequate decongestion and renal preservation a key clinical challenge [7].

Clinical Examination

Physical examination findings suggestive of CHF include tachypnea, increased respiratory effort, muffled lung sounds (pleural effusion) or crackles (pulmonary edema), a cardiac murmur (grades I–VI/VI) or gallop sound (S3 or S4), jugular venous distension, and hypothermia or cold extremities in decompensated cases [1][5]. Importantly, up to 50% of cats with significant cardiomyopathy may lack a murmur, so its absence does not rule out cardiac disease [2].

Thoracic Radiography

Chest radiographs are a primary emergency diagnostic tool. Findings consistent with left-sided CHF include pulmonary venous distension, a diffuse or patchy interstitial-to-alveolar pulmonary infiltrate (pulmonary edema), and cardiomegaly [5]. Pleural effusion appears as soft tissue opacity obliterating cardiac and diaphragmatic margins. The "valentine heart" silhouette (biatrial enlargement) is a classic but not universal finding. Differentiation of cardiogenic pulmonary edema from non-cardiogenic causes is essential [4].

Echocardiography

Echocardiography is the gold-standard diagnostic modality for definitive classification of the underlying cardiomyopathy and assessment of cardiac function [1]. Key measurements include left ventricular wall thickness (diastolic interventricular septum and free wall ≥6 mm in the absence of other causes is consistent with HCM), left ventricular internal diameter, systolic function (fractional shortening, ejection fraction), left atrial size (LA:Ao ratio >1.5 is considered enlarged), and Doppler assessment of diastolic filling patterns [2]. Detection of spontaneous echocardiographic contrast ("smoke") or left auricular thrombus identifies cats at high ATE risk [1].

Biomarkers

• ·NT-proBNP (N-terminal pro-B-type natriuretic peptide): A cardiac biomarker released in response to myocardial stretch. Elevated values strongly support cardiac disease as the cause of respiratory distress; a species-specific feline assay is available. Point-of-care testing is particularly useful in dyspneic cats where stress during echocardiography is a concern [1][5].
• ·Cardiac troponin I (cTnI): Elevated in myocardial injury; useful for identifying significant myocardial damage and may have prognostic value [1].

Laboratory Testing (Clinicopathological Indicators)

Routine bloodwork is essential to assess systemic consequences of CHF, guide therapy, and identify comorbidities:

• ·BUN (Blood Urea Nitrogen) / CREA (Creatinine): Frequently elevated (azotemia) due to reduced renal perfusion (prerenal), CRS, or as a consequence of diuretic therapy [7]. Baseline and serial monitoring are mandatory.
• ·Electrolytes (Na⁺, K⁺): Hypokalemia and hyponatremia may develop secondary to furosemide therapy or RAAS activation. Hyperkalemia is possible with ACE inhibitor or spironolactone use [3].
• ·ALT (Alanine Aminotransferase) / TBIL (Total Bilirubin): May be mildly to moderately elevated in right-sided or biventricular failure due to hepatic venous congestion.
• ·ALB (Albumin) / GLOB (Globulin) / Total Protein: Hypoalbuminemia may develop in chronic disease and contributes to reduced oncotic pressure, worsening edema formation.
• ·HCT (Hematocrit): Anemia may exacerbate CHF by increasing cardiac workload; polycythemia is rarely a contributing factor. Dehydration or hemoconcentration from diuresis may artificially elevate HCT.
• ·PLT (Platelets): Thrombocytopenia may be observed post-ATE due to platelet consumption. Platelet activation plays a role in thrombus formation [2].
• ·WBC (White Blood Cell Count): Generally unremarkable unless concurrent infection or systemic inflammation (e.g., post-ATE inflammatory response) is present.
• ·T4 (Total Thyroxine): Hyperthyroidism is an important reversible cause of secondary cardiac hypertrophy that must be excluded, particularly in older cats [1].
• ·Blood Pressure: Systemic hypertension (>160 mmHg systolic) must be identified as a contributing or primary etiology [1].

Electrocardiography (ECG)

ECG may reveal tachyarrhythmias (atrial fibrillation, ventricular tachycardia, supraventricular tachycardia), conduction disturbances (left bundle branch block), or evidence of chamber enlargement, all of which may complicate or contribute to CHF [1][5].

Differentiating Cardiogenic from Non-Cardiogenic Causes

Respiratory distress in cats has a broad differential including asthma/bronchitis, pneumonia, pyothorax, chylothorax, and non-cardiogenic pulmonary edema (NCPE) [4]. The combination of echocardiography, NT-proBNP, thoracic radiography, and response to emergency therapy helps establish a cardiogenic versus non-cardiogenic etiology [1][4].

Emergency / Acute Decompensated CHF

Stabilization takes absolute priority over diagnostics in the acutely dyspneic patient:

• ·Oxygen supplementation: Flow-by, mask, or oxygen cage to correct hypoxemia with minimal patient stress [5].
• ·Minimize handling: Cats with respiratory distress are highly stress-sensitive; aggressive restraint can precipitate cardiorespiratory arrest [1].
• ·Furosemide (loop diuretic): The cornerstone of acute CHF management. Administered IV or IM at 1–2 mg/kg initially, repeated every 1–4 hours as needed, titrated to respiratory rate response. Furosemide reduces preload by promoting rapid natriuresis and diuresis [1][5].
• ·Thoracocentesis: Pleural effusion should be drained promptly when present, as it is immediately life-saving and rapidly improves respiratory function. Pericardiocentesis if clinically indicated [1].
• ·Nitroglycerine (topical): Occasionally used as a venodilator in acute pulmonary edema, though evidence in cats is limited [5].
• ·Sedation/anxiolytics: Butorphanol (0.1–0.2 mg/kg IV/IM) may be used judiciously to reduce respiratory effort and anxiety [1].

Chronic / Maintenance Therapy

Once stabilized, long-term management aims to prevent fluid re-accumulation, reduce neurohormonal activation, and slow disease progression:

• ·Furosemide (oral): Continued at the lowest effective dose (typically 1–2 mg/kg PO q12–24h), titrated to maintain resting respiratory rate <30 breaths/min [1]. Chronic use requires monitoring of renal function and electrolytes.
• ·Spironolactone: An aldosterone antagonist with diuretic and antifibrotic properties. Used as an adjunct to furosemide; may provide cardiac remodeling benefits via RAAS suppression [3]. Caution regarding hyperkalemia.
• ·ACE Inhibitors (e.g., enalapril, benazepril): Inhibit angiotensin-converting enzyme, reducing angiotensin II and aldosterone levels, thereby attenuating RAAS-driven fibrosis and fluid retention [3]. Commonly used in chronic CHF management, though evidence in cats is less robust than in dogs.
• ·Pimobendan: A phosphodiesterase III inhibitor and calcium sensitizer that increases myocardial contractility and produces vasodilation. Evidence is emerging for benefit in feline CHF, particularly in cats with systolic dysfunction or as adjunctive therapy, and a 2025 evidence-based review has summarized its growing role in cardiomyopathy management [8]. Its use in HCM with dynamic left ventricular outflow tract (LVOT) obstruction requires careful evaluation due to theoretical concerns about worsening obstruction [8].
• ·Atenolol: A beta-1 selective adrenergic blocker used in HCM to reduce heart rate, increase diastolic filling time, and manage dynamic LVOT obstruction. Particularly beneficial in cats with resting or provocable LVOT obstruction [2].
• ·Diltiazem: A calcium channel blocker that reduces heart rate and improves myocardial relaxation; historically used in HCM but largely superseded by atenolol in many practices [2].
• ·Antithrombotic therapy: Due to the high risk of ATE, all cats with left atrial enlargement should receive antithrombotic prophylaxis. Options include clopidogrel (18.75 mg PO q24h; shown superior to aspirin in the FATCAT study) alone or combined with aspirin; low-molecular-weight heparin (e.g., dalteparin) may be considered in high-risk cases [1][2].
• ·Taurine supplementation: Indicated in cats with DCM if taurine deficiency is suspected or confirmed [6].

Monitoring and Home Surveillance

Owners should be instructed to monitor resting respiratory rate (RR) at home. A RR >30 breaths/min at rest should prompt immediate veterinary contact. Recheck visits typically include body weight, RR, thoracic auscultation, blood pressure, and serial biochemistry (BUN, creatinine, electrolytes) to monitor for azotemia and electrolyte disturbances [1][7].

Prognosis in feline CHF is guarded to poor and is highly variable, depending on the underlying cardiomyopathy phenotype, severity of cardiac remodeling, presence of comorbidities, and response to therapy [1].

Overall survival following first episode of CHF:

• ·Median survival times reported in cats following first onset of CHF are generally in the range of 3 to 18 months, though individual cats may live considerably longer with optimal management [1][2].
• ·Cats with HCM presenting in CHF have reported median survival times of approximately 92–563 days depending on the study population and treatments used [2].
• ·Cats with RCM or unclassified cardiomyopathy presenting in CHF tend to have shorter survival times than HCM cats, with median survivals often less than 3–6 months [6].
• ·DCM carries a variable prognosis; taurine-responsive DCM may show significant functional recovery, while non-taurine-responsive cases have a poor prognosis [6].

Prognostic factors associated with shorter survival:

• ·Concurrent ATE at presentation (median survival after ATE in cats with cardiomyopathy is reported as weeks to a few months; approximately 33–50% of cats die or are euthanized within the first 24–72 hours following ATE) [1][2]
• ·Left atrial enlargement (LA:Ao ratio >2.0)
• ·Pleural effusion vs. isolated pulmonary edema (pleural effusion may indicate more advanced biventricular failure)
• ·Severe azotemia or CRS at presentation [7]
• ·Hypothermia at presentation
• ·Sustained tachyarrhythmias (e.g., atrial fibrillation)
• ·Low serum albumin

Recurrence: Fluid re-accumulation is common and expected; many cats require emergency re-hospitalization within weeks to months of initial presentation. Each decompensation episode carries inherent mortality risk and progressive cardiac deterioration [5].

Subclinical cardiomyopathy (pre-CHF): In contrast to overt CHF, cats with subclinical (occult) cardiomyopathy without CHF may have a normal life expectancy if disease is mild, though progression is unpredictable [1][2].

Genetic and Breed-Level Screening

HCM has a documented heritable basis in certain breeds. Mutations in the cardiac myosin-binding protein C gene (MYBPC3) have been identified in Maine Coon and Ragdoll cats; genetic testing for these specific mutations is available and recommended for breeding stock [2]. However, these mutations account for only a subset of feline HCM cases, and a negative genetic test does not exclude HCM in other breeds or mixed-breed cats [1][2].

Echocardiographic screening programs are recommended for breeds with elevated HCM prevalence (Maine Coon, Ragdoll, British Shorthair, Sphynx, Bengal, and others), and affected cats should be excluded from breeding programs [1][2].

Dietary Management

Ensuring adequate dietary taurine intake is important for prevention of nutritional DCM. Commercial complete and balanced feline diets meet minimum taurine requirements, but cats fed homemade, raw, or exotic ingredient diets may be at risk [6]. Routine taurine supplementation or dietary assessment is warranted in cats with DCM.

Management of Predisposing Conditions

Early diagnosis and control of systemic hypertension and hyperthyroidism can prevent or minimize secondary cardiac hypertrophy that may progress to CHF [1]. Regular veterinary check-ups, including blood pressure measurement and thyroid assessment in middle-aged to senior cats, are key preventive measures.

Monitoring High-Risk Cats

Cats diagnosed with subclinical cardiomyopathy—particularly those with significant left atrial enlargement—should undergo regular echocardiographic and clinical monitoring (every 6–12 months) to detect early decompensation and initiate therapy promptly [1]. Owner education on home respiratory rate monitoring allows earlier detection of CHF onset.

No Vaccine Available

There is no vaccine for feline cardiomyopathy or CHF. Prevention is focused on genetic screening, dietary adequacy, management of comorbidities, and surveillance of at-risk populations [1][2].